Anavex Life Sciences Corp.AVXLNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
0.68%
↓ 95% below average
Average (39q)
14.25%
Historical baseline
Range
High:373.00%
Low:-52.94%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q2 2025 | 0.68% |
| Q1 2025 | -5.30% |
| Q4 2024 | -9.60% |
| Q3 2024 | -2.65% |
| Q2 2024 | 22.01% |
| Q1 2024 | 12.03% |
| Q4 2023 | -13.69% |
| Q3 2023 | -2.16% |
| Q2 2023 | -2.60% |
| Q1 2023 | -12.51% |
| Q4 2022 | 6.03% |
| Q3 2022 | 22.73% |
| Q2 2022 | 7.76% |
| Q1 2022 | -0.59% |
| Q4 2021 | -7.65% |
| Q3 2021 | 4.55% |
| Q2 2021 | 33.39% |
| Q1 2021 | -15.20% |
| Q4 2020 | 29.83% |
| Q3 2020 | -9.22% |
| Q2 2020 | 11.10% |
| Q1 2020 | -4.66% |
| Q4 2019 | 34.77% |
| Q3 2019 | -18.18% |
| Q2 2019 | -5.28% |
| Q1 2019 | 6.43% |
| Q4 2018 | 29.61% |
| Q3 2018 | 47.00% |
| Q2 2018 | -7.61% |
| Q1 2018 | 20.45% |
| Q4 2017 | -29.77% |
| Q3 2017 | 66.78% |
| Q2 2017 | -7.74% |
| Q1 2017 | 22.09% |
| Q4 2016 | -52.94% |
| Q3 2016 | 373.00% |
| Q2 2016 | -15.92% |
| Q1 2016 | -6.27% |
| Q4 2015 | 55.93% |
| Q3 2015 | -6.62% |